Latest News for: aacr

Edit

D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation ...

Magic Valley 20 Mar 2026
(PRNewsfoto/D3 Bio, Inc.) ... .
Edit

D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session

PR Newswire 20 Mar 2026
"We are excited to present new clinical and preclinical data at this year's AACR Annual Meeting" said George Chen, Founder, Chairman and Chief Executive Officer of D3 Bio.
Edit

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Norfolk Daily News 19 Mar 2026
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq ... .
Edit

Phanes Therapeutics to Present Three Clinical Posters at AACR 2026

Elko Daily Free Press 19 Mar 2026
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Phanes ...
Edit

Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR ...

The Bay City Tribune 19 Mar 2026
HOUSTON, March 18, 2026 /PRNewswire/ -- Diakonos Oncology ...
Edit

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 (Form 8-K) (Oncolytics Biotech Inc)

Public Technologies 19 Mar 2026
) Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026.
Edit

Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026

The Joplin Globe 18 Mar 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Mar 17, 2026-- ... .
Edit

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong ...

The Daily Record - Dunn 18 Mar 2026
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with ....
Edit

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing

Hastings Tribune 18 Mar 2026
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ... .
Edit

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

The Daily Record - Dunn 18 Mar 2026
SHANGHAI and HONG KONG, March 17, 2026 ....
Edit

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

Enid News & Eagle 18 Mar 2026
IPN01203 data to be presented at coveted New Drugs on ...
Edit

Zymeworks Announces Presentations for Ziihera� (zanidatamab-hrii) at 2026 AACR Annual Meeting

Nasdaq Globe Newswire 18 Mar 2026
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology. Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology ... .
Edit

New AACR Data Expand Evidence for TKa In Immunotherapy-Treated Patients and CDK Inhibitor Dose Optimization

The Daily Record - Dunn 18 Mar 2026
UPPSALA, SE / ACCESS Newswire / March 18, 2026 / Biovica International (STO.BIOVIC-B)(STO.BIOVIC.B)(FRA.9II) - Biovica, ....
Edit

New data from Investigator‑Initiated Study Evaluating Alligator Bioscience's Mitazalimab to be Presented at AACR Annual ...

The Daily Record - Dunn 18 Mar 2026
LUND, SE / ACCESS Newswire / March 18, 2026 / Alligator Bioscience (STO.ATORX), a clinical-stage biotechnology company ....
Edit

Circle Pharma to Present New Clinical and Preclinical Data at AACR 2026

Cadillac News 18 Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 18, 2026-- ... .

Article Search

tools
×
×
×
×